• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名伴有基因重排阳性的大细胞神经内分泌癌患者的原发灶与转移灶之间存在异质性肿瘤-免疫微环境。

Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with Rearrangement-Positive Large Cell Neuroendocrine Carcinoma.

机构信息

Department of Respiratory Medicine, Kumamoto Chuo Hospital, Kumamoto-shi, Kumamoto 860-8556, Japan.

Department of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto-shi, Kumamoto 860-8556, Japan.

出版信息

Int J Mol Sci. 2020 Dec 19;21(24):9705. doi: 10.3390/ijms21249705.

DOI:10.3390/ijms21249705
PMID:33352665
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7767140/
Abstract

Evolution of tumor-immune microenviroments (TIMEs) occurs during tumor growth and dissemination. Understanding inter-site tumor-immune heterogeneity is essential to harness the immune system for cancer therapy. While the development of immunotherapy against lung cancer with driver mutations and neuroendocrine tumors is ongoing, little is known about the TIME of large cell neuroendocrine carcinoma (LCNEC) or () rearrangement-positive lung cancer. We present a case study of a 32-year-old female patient with -rearrangement-positive LCNEC, who had multiple distant metastases including mediastinal lymph-node, bilateral breasts, multiple bones, liver and brain. Multiple biopsy samples obtained from primary lung and three metastatic tumors were analyzed by fluorescent multiplex immunohistochemistry. Tissue localizations of tumor-infiltrating lymphocytes in the tumor nest and surrounding stroma were evaluated. T cell and B cell infiltrations were decreased with distance from primary lung lesion. Although each tumor displayed a unique TIME, all tumors exhibited concomitant regression after treatment with an ALK-inhibitor. This study provides the first evidence of the coexistence of distinct TIME within a single individual with -rearrangement-positive LCNEC. The present study contributes to our understanding of heterogeneous TIMEs between primary and metastatic lesions and provides new insights into the complex interplay between host-immunity and cancer cells in primary and metastatic lesions.

摘要

肿瘤免疫微环境(TIMEs)在肿瘤生长和扩散过程中发生演变。了解肿瘤免疫异质性对于利用免疫系统进行癌症治疗至关重要。虽然针对具有驱动突变和神经内分泌肿瘤的肺癌的免疫疗法正在不断发展,但对于大细胞神经内分泌癌(LCNEC)或 ()重排阳性肺癌的 TIMEs 知之甚少。我们报告了一例 32 岁女性 -重排阳性 LCNEC 患者的病例研究,该患者有多发性远处转移,包括纵隔淋巴结、双侧乳房、多处骨骼、肝脏和大脑。对原发肺部和三个转移瘤的多个活检样本进行了荧光多重免疫组织化学分析。评估了肿瘤巢和周围基质中浸润性淋巴细胞的组织定位。T 细胞和 B 细胞浸润随着与原发肺部病变的距离增加而减少。尽管每个肿瘤都显示出独特的 TIMEs,但在使用 ALK 抑制剂治疗后,所有肿瘤均显示出协同消退。这项研究首次提供了在单个 -重排阳性 LCNEC 个体中存在不同 TIMEs 的证据。本研究有助于我们了解原发和转移病变之间异质性 TIMEs,并为宿主免疫和原发和转移病变中癌细胞之间的复杂相互作用提供了新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48eb/7767140/fda369acd2b8/ijms-21-09705-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48eb/7767140/ff161828036a/ijms-21-09705-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48eb/7767140/89253675dd97/ijms-21-09705-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48eb/7767140/c127d4eff9ed/ijms-21-09705-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48eb/7767140/61a435a3dd7e/ijms-21-09705-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48eb/7767140/600fb6e4a277/ijms-21-09705-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48eb/7767140/fda369acd2b8/ijms-21-09705-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48eb/7767140/ff161828036a/ijms-21-09705-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48eb/7767140/89253675dd97/ijms-21-09705-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48eb/7767140/c127d4eff9ed/ijms-21-09705-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48eb/7767140/61a435a3dd7e/ijms-21-09705-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48eb/7767140/600fb6e4a277/ijms-21-09705-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48eb/7767140/fda369acd2b8/ijms-21-09705-g006.jpg

相似文献

1
Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with Rearrangement-Positive Large Cell Neuroendocrine Carcinoma.一名伴有基因重排阳性的大细胞神经内分泌癌患者的原发灶与转移灶之间存在异质性肿瘤-免疫微环境。
Int J Mol Sci. 2020 Dec 19;21(24):9705. doi: 10.3390/ijms21249705.
2
Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.伴有间变性淋巴瘤激酶(ALK)重排且对阿来替尼有反应的大细胞神经内分泌癌
Intern Med. 2018 Mar 1;57(5):713-716. doi: 10.2169/internalmedicine.9368-17. Epub 2017 Nov 20.
3
Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel Fusion Oncokinase.ALK免疫组化在肺大细胞神经内分泌癌最佳治疗策略中的应用及一种新型融合癌激酶的鉴定
Anticancer Res. 2019 Jan;39(1):413-420. doi: 10.21873/anticanres.13127.
4
A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.ALK 重排型肺腺癌合并神经内分泌癌伴广泛骨转移及阿来替尼部分缓解 1 例
Curr Oncol. 2022 Feb 3;29(2):848-852. doi: 10.3390/curroncol29020072.
5
Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.下一代测序在肺大细胞神经内分泌癌中鉴定出一种新型的对克唑替尼敏感的PLB1-ALK重排。
Clin Lung Cancer. 2021 May;22(3):e366-e370. doi: 10.1016/j.cllc.2020.05.026. Epub 2020 Jun 2.
6
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.PD-L1 表达和 CD8+T 细胞浸润在 EGFR 突变和 ALK 重排肺癌患者中的临床意义。
Lung Cancer. 2018 Nov;125:86-92. doi: 10.1016/j.lungcan.2018.09.010. Epub 2018 Sep 14.
7
Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with Rearrangement.免疫检查点抑制剂单药治疗伴有重排的晚期非小细胞肺癌的疗效。
Int J Mol Sci. 2020 Apr 9;21(7):2623. doi: 10.3390/ijms21072623.
8
Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.ALK 重排肺癌中对 ALK 抑制剂获得性耐药相关的 PD-L1 表达改变。
Cancer Res Treat. 2019 Jul;51(3):1231-1240. doi: 10.4143/crt.2018.486. Epub 2018 Dec 31.
9
Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.治疗间变性淋巴瘤激酶重排非小细胞肺癌脑转移
Oncol Res Treat. 2019;42(11):599-606. doi: 10.1159/000502755. Epub 2019 Sep 17.
10
Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.ALK 重排阳性腺癌转化的非小细胞肺癌伴神经内分泌分化中 CD133 和 BCL-2 的过表达。
Pathol Int. 2019 May;69(5):294-299. doi: 10.1111/pin.12782. Epub 2019 Mar 22.

引用本文的文献

1
Misdiagnosis of bilateral breast metastases as primary benign tumors secondary to lung large-cell neuroendocrine carcinoma: a case report.双侧乳腺转移瘤误诊为肺大细胞神经内分泌癌继发的原发性良性肿瘤:一例报告
Discov Oncol. 2025 Jun 14;16(1):1101. doi: 10.1007/s12672-025-02855-y.
2
Investigation of Metabolic and Inflammatory Disorder in the Aging FGF21 Knockout Mouse.衰老 FGF21 基因敲除小鼠代谢及炎症紊乱的研究。
Inflammation. 2024 Dec;47(6):2173-2195. doi: 10.1007/s10753-024-02032-3. Epub 2024 Apr 24.
3
Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review.

本文引用的文献

1
Heterogeneous tumor-immune microenvironments between primary and metastatic carcinoid tumors differentially respond to anti-PD-L1 antibody therapy.原发和转移性类癌肿瘤之间异质性的肿瘤免疫微环境对抗 PD-L1 抗体治疗的反应不同。
Thorac Cancer. 2021 Feb;12(3):397-401. doi: 10.1111/1759-7714.13772. Epub 2020 Dec 9.
2
Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing.抗癌治疗中靶向肿瘤相关巨噬细胞:说服“叛徒”改邪归正
J Clin Med. 2020 Oct 8;9(10):3226. doi: 10.3390/jcm9103226.
3
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
两例病例报告:EML4-ALK重排的大细胞神经内分泌癌及文献综述
Front Oncol. 2023 Nov 1;13:1227980. doi: 10.3389/fonc.2023.1227980. eCollection 2023.
4
Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report.序贯使用ALK抑制剂成功治疗ALK阳性肺大细胞神经内分泌癌:一例报告
JTO Clin Res Rep. 2023 Jun 15;4(7):100538. doi: 10.1016/j.jtocrr.2023.100538. eCollection 2023 Jul.
5
Gallbladder neuroendocrine carcinoma: A report of two cases and literature review.胆囊神经内分泌癌:两例报告及文献综述
Oncol Lett. 2023 Apr 13;25(6):229. doi: 10.3892/ol.2023.13815. eCollection 2023 Jun.
6
Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung Cancer.肺癌中存在脑红蛋白阳性、肿瘤浸润耗竭 T 细胞的临床意义和分子特征
Int J Mol Sci. 2022 Nov 8;23(22):13723. doi: 10.3390/ijms232213723.
7
Metastatic pulmonary carcinoids with fusion response to ALK inhibitors: two case reports and review of literature.对ALK抑制剂有融合反应的转移性肺类癌:两例病例报告及文献综述
Transl Lung Cancer Res. 2022 Jun;11(6):1176-1184. doi: 10.21037/tlcr-22-394.
8
Case Report: A Pregnant Woman Diagnosed as ALK-Rearrangement Lung Large Cell Neuroendocrine Cancer With Brain Metastasis.病例报告:一名被诊断为ALK重排的肺大细胞神经内分泌癌伴脑转移的孕妇。
Front Oncol. 2022 Feb 25;12:823813. doi: 10.3389/fonc.2022.823813. eCollection 2022.
9
Management of Large Cell Neuroendocrine Carcinoma.大细胞神经内分泌癌的管理
Front Oncol. 2021 Aug 27;11:653162. doi: 10.3389/fonc.2021.653162. eCollection 2021.
10
Dramatic response to alectinib in an -positive LCNEC patient with a poor performance status: A case report.对一名体能状态较差的ALK阳性大细胞神经内分泌癌(LCNEC)患者使用阿来替尼治疗的显著反应:病例报告
Respirol Case Rep. 2021 Aug 3;9(9):e0817. doi: 10.1002/rcr2.817. eCollection 2021 Sep.
单细胞 RNA 测序揭示人类肺癌的治疗诱导进化。
Cell. 2020 Sep 3;182(5):1232-1251.e22. doi: 10.1016/j.cell.2020.07.017. Epub 2020 Aug 20.
4
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade.髓系细胞作为免疫检查点阻断的临床生物标志物。
Front Immunol. 2020 Jul 24;11:1590. doi: 10.3389/fimmu.2020.01590. eCollection 2020.
5
Association of Probiotic Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer.益生菌治疗与肺癌患者的生存和免疫检查点阻断反应的关系。
Cancer Immunol Res. 2020 Oct;8(10):1236-1242. doi: 10.1158/2326-6066.CIR-20-0051. Epub 2020 Jul 14.
6
The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells.三维 DNA 荧光原位杂交(3D DNA FISH)在非小细胞肺癌(NSCLC)循环肿瘤细胞中检测间变性淋巴瘤激酶(ALK)的应用。
Cells. 2020 Jun 15;9(6):1465. doi: 10.3390/cells9061465.
7
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.依匹木单抗和纳武利尤单抗治疗晚期神经内分泌肿瘤患者的免疫治疗:罕见癌症 CA209-538 临床试验的亚组分析。
Clin Cancer Res. 2020 Sep 1;26(17):4454-4459. doi: 10.1158/1078-0432.CCR-20-0621. Epub 2020 Jun 12.
8
Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.真实世界中治疗模式与间变性淋巴瘤激酶(ALK)酪氨酸激酶抑制剂治疗ALK+非小细胞肺癌的无进展生存期。
Oncologist. 2020 Oct;25(10):867-877. doi: 10.1634/theoncologist.2020-0011. Epub 2020 Jul 23.
9
Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.ALK 重排阳性非小细胞肺癌且一般状况较差患者的生存分析:九州肺癌研究组 1401 研究的更新结果。
Oncologist. 2020 Apr;25(4):306-e618. doi: 10.1634/theoncologist.2019-0728. Epub 2019 Oct 30.
10
Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with Rearrangement.免疫检查点抑制剂单药治疗伴有重排的晚期非小细胞肺癌的疗效。
Int J Mol Sci. 2020 Apr 9;21(7):2623. doi: 10.3390/ijms21072623.